Resumen

GARCIA-ALVAREZ, José L.  y  GARCIA-VIGIL, José L.. Guidelines for clinical management of SARS-Cov-2 infection. Gac. Méd. Méx [online]. 2020, vol.156, n.6, pp.586-594.  Epub 27-Mayo-2021. ISSN 2696-1288.  https://doi.org/10.24875/gmm.20000317.

In SARS-CoV-2 infection (COVID-19), the most common manifestations involve the upper airways; in complicated cases, bilateral interstitial pneumonia, severe acute respiratory failure and multiple organ failure occur, which require hospital treatment and ventilatory support with nasal cannula or mask and high flow oxygen, or orotracheal intubation and mechanical ventilation. There are no specific antivirals, and thus management is symptomatic, as well as with antiplatelet drugs (acetylsalicylic acid, dipyridamole), low molecular weight heparin when there is hypercoagulability (increased D-dimer), dexamethasone when inflammation indicators are elevated; experimentally, under informed consent, antibiotics are used according to microbiological results, as well as interferon beta 1b, favipiravir, tocilizumab, ivermectin and immunoglobulin G. When gastroenteritis occurs, nitazoxanide can be indicated.

Palabras llave : SARS-CoV-2; COVID-19; Pneumonia; Favipiravir; Tocilizumab; Ivermectin; Immunoglobulin G; Nitazoxanide.